PRESS RELEASES

Date	Title
Dec 4, 2019	Ardelyx Announces Proposed Public Offering of Common Stock
Dec 3, 2019	Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
Dec 2, 2019	Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
Nov 26, 2019	Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
Nov 25, 2019	Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
Nov 6, 2019	Ardelyx Announces Presentation at Kidney Week 2019
Nov 6, 2019	Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
Oct 10, 2019	Ardelyx to Host Analyst Day in New York
Sep 17, 2019	Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 12, 2019	Ardelyx Receives FDA Approval for IBSRELA® (Tenapanor), an NHE3 Sodium Transport Inhibitor, for the Treatment of Irritable Bowel Syndrome with Constipation

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 510.745.1700

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com